Business Development
Building relationships with industry and academia
Our Business Development division is responsible for managing the work flowing in and out of our Centre for Therapeutics Discovery (CTD).
They are responsible for:
• enabling partnerships where CTD will work on programmes on behalf of industry;
• licensing small molecules and therapeutic antibodies generated by CTD; and
• bringing small molecule and therapeutic antibody targets from academia into the drug discovery pipeline.
News feed
Two new collaborations with Prof Mauro Perretti at the William Harvey Research Institute, Queen Mary University of London (QMUL) launched
Collaboration launched with Prof Adrian Clark and Dr Li Chan at the William Harvey Research Institute, Queen Mary University of London
MRCT have recently launched a second collaboration with the University of Bristol in the area of pain medicine.
Substituted aminopyrimidine protein kinase B (PknB) inhibitors show activity against Mycobacterium tuberculosis